Skandinaviska Enskilda Banken AB publ Sells 100 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Skandinaviska Enskilda Banken AB publ lessened its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,731 shares of the medical research company’s stock after selling 100 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Bio-Rad Laboratories were worth $1,218,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Assetmark Inc. lifted its holdings in shares of Bio-Rad Laboratories by 84.8% during the third quarter. Assetmark Inc. now owns 305 shares of the medical research company’s stock worth $102,000 after buying an additional 140 shares during the last quarter. Atria Investments Inc raised its stake in Bio-Rad Laboratories by 9.2% during the 3rd quarter. Atria Investments Inc now owns 2,645 shares of the medical research company’s stock valued at $885,000 after purchasing an additional 223 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in Bio-Rad Laboratories by 0.9% in the 3rd quarter. Victory Capital Management Inc. now owns 21,294 shares of the medical research company’s stock valued at $7,125,000 after purchasing an additional 186 shares during the period. KBC Group NV grew its position in Bio-Rad Laboratories by 82.6% in the 3rd quarter. KBC Group NV now owns 3,095 shares of the medical research company’s stock worth $1,036,000 after purchasing an additional 1,400 shares during the last quarter. Finally, OneDigital Investment Advisors LLC bought a new position in shares of Bio-Rad Laboratories during the 3rd quarter worth about $220,000. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Up 0.7 %

NYSE BIO opened at $256.35 on Tuesday. Bio-Rad Laboratories, Inc. has a 1-year low of $244.00 and a 1-year high of $387.99. The company has a market capitalization of $7.18 billion, a price-to-earnings ratio of -3.94 and a beta of 0.98. The stock’s 50 day moving average is $310.23 and its two-hundred day moving average is $327.46. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, Wells Fargo & Company lowered their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.